Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer
The targeted drug Cyramza combined with chemotherapy produced a disease-control rate of 81% in a trial of previously treated gastric cancer patients.
